Atara Biotherapeutics, Inc.
Expected move
No implied move.
Next report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Atara Biotherapeutics, Inc.
8.10
SentencePursuant to the Fujifilm MSA, FDB will supply us with specified quantities of our product and product candidates, manufactured in accordance with cGMP standards.
ATRA 10-Kaccession 0001193125-26-108361
SentenceIn June 2015, we licensed certain patent rights, know-how and a library of T cells and cell lines specific to EBV from MSK under an exclusive license agreement.
ATRA 10-Kaccession 0001193125-26-108361
SentenceIn October 2015, we entered into an exclusive license agreement and a research and development collaboration agreement with QIMR Berghofer.
ATRA 10-Kaccession 0001193125-26-108361
SentenceIn December 2022, we entered into a Purchase and Sale Agreement (HCRx Agreement) with HCR Molag Fund L.P. (HCRx) pursuant to which we sold a portion of our right to receive royalties and certain milestones in Ebvallo under the Pierre Fabre Commercialization Agreement to HCRx for a total investment amount of $31.0 million, subject to a repayment cap between 185% and 250% of the total investment amount by HCRx.
ATRA 10-Kaccession 0001193125-26-108361
SentenceIn October 2021, we entered into the Pierre Fabre Commercialization Agreement (Pierre Fabre Commercialization Agreement), pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute Ebvallo in Europe and select emerging markets in the Middle East, Africa, Eastern Europe and Central Asia (Initial Territory).
ATRA 10-Kaccession 0001193125-26-108361
Atara Biotherapeutics has 3 disclosed suppliers and 2 disclosed customers in SEC filings.